View Future GrowthGilead Sciences 過去の業績過去 基準チェック /56Gilead Sciencesは、平均年間9.6%の収益成長を遂げていますが、 Biotechs業界の収益は、年間 成長しています。収益は、平均年間15.6% 2.3%収益成長率で 成長しています。 Gilead Sciencesの自己資本利益率は37.6%であり、純利益率は28.9%です。主要情報9.56%収益成長率9.80%EPS成長率Biotechs 業界の成長12.91%収益成長率2.28%株主資本利益率37.62%ネット・マージン28.90%次回の業績アップデート07 May 2026最近の業績更新Gilead Sciences, Inc. to Report Q1, 2026 Results on May 07, 2026Apr 23Full year 2025 earnings released: EPS: US$6.84 (vs US$0.39 in FY 2024) Feb 11Gilead Sciences, Inc. to Report Q4, 2025 Results on Feb 10, 2026Jan 28Third quarter 2025 earnings released: EPS: US$2.46 (vs US$1.01 in 3Q 2024) Nov 01Gilead Sciences, Inc. to Report Q3, 2025 Results on Oct 30, 2025Oct 10Second quarter 2025 earnings released: EPS: US$1.57 (vs US$1.29 in 2Q 2024) Aug 08すべての更新を表示Recent updatesGilead Sciences, Inc. Receives U.S. FDA Priority Review For Once-Daily HIV Treatment Bictegravir Plus LenacapavirMay 02Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of 77.2% stake in Arcellx, Inc. (NasdaqGS:ACLX) from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others.Apr 29Gilead Sciences, Inc. to Report Q1, 2026 Results on May 07, 2026Apr 23Insufficient new directors Apr 14Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Tubulis GmbH from a group of shareholders for $5 billion.Apr 08Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Ouro Medicines, Inc. from Keymed Biosciences Inc. (SEHK:2162) and others for $2.2 billion.Mar 24+ 1 more updateGilead Sciences, Inc., Annual General Meeting, Apr 30, 2026Mar 23Upcoming dividend of US$0.82 per share Mar 06Gilead Sciences, Inc. Announces the Presentation of New Phase 3 ARTISTRY-1 and ARTISTRY-2 Trial Data At CROI 2026Feb 26Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an agreement to acquire the remaining 88.50% stake in Arcellx, Inc. (NasdaqGS:ACLX) from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others for approximately $6.6 billion.Feb 23Gilead Sciences, Inc. to Present New Hiv Treatment and Prevention Data At Croi 2026, with A Focus on Expanding OptionsFeb 17Fourth quarter dividend of US$0.82 announced Feb 14New minor risk - Financial position Feb 13Full year 2025 earnings released: EPS: US$6.84 (vs US$0.39 in FY 2024) Feb 11Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2026Feb 11+ 1 more updateFda Approves Label Update for Kite's Yescarta®? for Relapsed/Refractory Primary Central Nervous System LymphomaFeb 06Gilead Sciences, Inc. to Report Q4, 2025 Results on Feb 10, 2026Jan 28Gilead Sciences, Inc. Announces New England Journal of Medicine Publishes Phase 3 ASCENT-04/KeyNOTE-D19 Results Supporting Trodelvy®? Plus Keytruda®? as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-Negative Breast CancerJan 22Gilead Sciences, Inc. Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Effective December 18, 2025Dec 18Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ARTISTRY-2 TrialDec 15Upcoming dividend of US$0.79 per share Dec 08Deborah H. Telman to No Longer Serve as Executive Vice President, Corporate Affairs and General Counsel of Gilead Sciences, Inc. as of December 5, 2025Nov 20Gilead Sciences, Inc. Joins Partners for Delivery of First Shipments of Breakthrough Twice-Yearly Lenacapavir for HIV Prevention to Sub-Saharan AfricaNov 18Gilead Sciences, Inc.'s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ART-1 TrialNov 13Gilead Sciences, Inc. Provides Update on Phase 3 ASCENT-07 StudyNov 07+ 1 more updateThird quarter dividend of US$0.79 announced Nov 03Gilead Sciences, Inc. announces Quarterly dividend, payable on December 30, 2025Nov 01Third quarter 2025 earnings released: EPS: US$2.46 (vs US$1.01 in 3Q 2024) Nov 01Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2025Oct 31Gilead Sciences, Inc. to Showcase Interim Long-Term Efficacy Data for Livdelzi (Seladelpar) in Primary Biliary Cholangitis (Pbc) and Investigational Bulevirtide in Chronic Hepatitis DeltaOct 23Gilead Sciences, Inc. Receives Health Canada Approval for the Treatment of Primary Biliary CholangitisOct 22Gilead Sciences, Inc. to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025Oct 20+ 1 more updateGilead Presents New Hiv Research Data At EACS 2025 – Driving Scientific Innovation in Treatment and PreventionOct 16Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care with New Data At Esmo 2025Oct 14Gilead Sciences, Inc. to Report Q3, 2025 Results on Oct 30, 2025Oct 10Upcoming dividend of US$0.79 per share Sep 08Gilead Sciences, Inc. Announces European Commission Authorizes Twice-Y Early Yeytuo (Lenacapavir) for HIV PreventionAug 26Second quarter dividend of US$0.79 announced Aug 17Second quarter 2025 earnings released: EPS: US$1.57 (vs US$1.29 in 2Q 2024) Aug 08Gilead Sciences, Inc. (NasdaqGS:GILD) announces an Equity Buyback for $6,000 million worth of its shares.Aug 08+ 2 more updatesGilead Receives Positive CHMP Opinions Under Accelerated Review from European Medicines Agency for Twice-Yearly HIV PrEP Option in the European UnionJul 25+ 1 more updateGilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for Hiv Prevention At Ias 2025Jul 14Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approves Yeztugo (Lanacapavir) as Pre-Exposure ProphylaxisJun 19Upcoming dividend of US$0.79 per share Jun 06Gilead Sciences, Inc. Announces Trodelvy Plus Keytruda®? Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast CancerJun 01Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-03 Study of TrodelvyMay 23Gilead's Livdelzi (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented At EASL 2025May 07+ 1 more updateFirst quarter dividend of US$0.79 announced May 05First quarter 2025 earnings released: EPS: US$1.06 (vs US$3.34 loss in 1Q 2024) Apr 30Gilead Sciences, Inc. to Present Latest Advancements Across Primary Biliary Cholangitis and Viral HepatitisApr 29Gilead Sciences, Inc. Declares Quarterly Dividend for the Second Quarter of 2025, Payable on June 27, 2025Apr 25+ 1 more updateGilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-04/KeyNOTE-D19 StudyApr 21Gilead Sciences, Inc. to Report Q1, 2025 Results on Apr 24, 2025Apr 11Gilead Sciences, Inc., Annual General Meeting, May 07, 2025Mar 28Gilead Sciences, Inc. Presents New HIV Treatment and Cure Research Data At CROI 2025, Including an Investigational Long-Acting, Twice-Y Early Therapy OptionMar 12+ 1 more updateUpcoming dividend of US$0.79 per share Mar 07European Medicines Agency Validates Gilead's Marketing Authorization Application and Eu-Medicines for All Application for Twice-Yearly Lenacapavir for Hiv PreventionFeb 25Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary CholangitisFeb 21Gilead Sciences, Inc. Announces U.S. FDA Acceptance of Its New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority ReviewFeb 18Fourth quarter dividend of US$0.79 announced Feb 14Full year 2024 earnings released: EPS: US$0.39 (vs US$4.54 in FY 2023) Feb 13Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2025Feb 12+ 1 more updateGilead Sciences, Inc. to Report Q4, 2024 Results on Feb 11, 2025Jan 29Insufficient new directors Jan 27Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary CholangitisDec 13+ 1 more updateKite, Gilead Company, Announces Results from Four Analyses That Continue to Demonstrate Durability of Response of Tecartus in Patients with R/R MCL and R/R B-ALL During 66th ASH Annual Meeting and ExpositionDec 10+ 1 more updateGilead Sciences, Inc.' Company Kite Presents New Data Underscoring Curative Potential of Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASHDec 09Upcoming dividend of US$0.77 per share Dec 07Chief Medical Officer recently sold Mex$36m worth of stock Dec 01Gilead Sciences, Inc. Announces New England Journal of Medicine Publication of PURPOSE 2 ResultsNov 28Gilead's Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary CholangitisNov 16Gilead Sciences, Inc. Presents Full Purpose 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV GlasgowNov 13Third quarter dividend of US$0.77 announced Nov 10Third quarter 2024 earnings released: EPS: US$1.01 (vs US$1.75 in 3Q 2023) Nov 08Gilead Sciences, Inc. Declares Quarterly Dividend for the Fourth Quarter of 2024, Payable on December 30, 2024Nov 07Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48Oct 21Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024Oct 10+ 1 more updateGilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention ConferenceOct 07Upcoming dividend of US$0.77 per share Sep 06Second quarter dividend of US$0.77 announced Aug 19Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDAAug 15Second quarter 2024 earnings released: EPS: US$1.29 (vs US$0.84 in 2Q 2023) Aug 09Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024Jul 26Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025Jul 17Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in AsiaJun 27収支内訳Gilead Sciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BMV:GILD * 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 2529,4438,5105,7085,68830 Sep 2529,0878,1105,7925,73430 Jun 2528,8636,3115,8505,78631 Mar 2528,7355,9655,8605,68531 Dec 2428,7544806,0005,81630 Sep 2428,2991265,7195,65530 Jun 2427,8051,0545,6245,72831 Mar 2427,4504856,1055,77831 Dec 2327,1165,6656,0625,75830 Sep 2327,3915,8766,5025,89530 Jun 2327,3825,4846,4015,57831 Mar 2327,0435,5835,9095,28031 Dec 2227,2814,5925,6734,97730 Sep 2227,1363,3345,3034,76830 Jun 2227,5154,1375,2804,72731 Mar 2227,4724,5155,2744,71431 Dec 2127,3056,2255,2464,60130 Sep 2127,4827,3945,0834,65530 Jun 2126,6385,1624,9994,71331 Mar 2125,5643014,8874,92431 Dec 2024,6891235,1124,92730 Sep 2023,1471,2684,6254,56030 Jun 2022,174-2574,5714,43231 Mar 2022,7164,9624,4274,00231 Dec 1922,4495,3864,3814,05530 Sep 1922,3652,6934,3084,08630 Jun 1922,3575,9554,2043,99531 Mar 1922,3205,8924,0894,31831 Dec 1822,1275,4554,0563,92030 Sep 1822,2811,5874,1774,21830 Jun 1823,1972,2084,1084,06831 Mar 1824,6903,4644,0253,74031 Dec 1726,1074,6283,8783,73430 Sep 1727,47811,6013,6183,59130 Jun 1728,46612,2133,5703,82631 Mar 1729,10112,6373,5634,44631 Dec 1630,39013,5013,3984,66630 Sep 1631,57615,0763,4724,41630 Jun 1632,37116,3463,5444,13531 Mar 1632,83917,3413,4663,46931 Dec 1532,63918,1083,4263,01430 Sep 1531,44716,9123,2362,95230 Jun 1529,19415,0433,2782,839質の高い収益: GILD *は 高品質の収益 を持っています。利益率の向上: GILD *の現在の純利益率 (28.9%)は、昨年(1.7%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: GILD *の収益は過去 5 年間で年間9.6%増加しました。成長の加速: GILD *の過去 1 年間の収益成長率 ( 1672.9% ) は、5 年間の平均 ( 年間9.6%を上回っています。収益対業界: GILD *の過去 1 年間の収益成長率 ( 1672.9% ) はBiotechs業界11.7%を上回りました。株主資本利益率高いROE: GILD *の 自己資本利益率 ( 37.62% ) は 高い ですが、この指標は負債レベルが高いために歪んでいます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/03 12:42終値2026/04/27 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Gilead Sciences, Inc. 27 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。66 アナリスト機関David ToungArgus Research CompanyBrian SkorneyBairdEmily FieldBarclays63 その他のアナリストを表示
Gilead Sciences, Inc. Receives U.S. FDA Priority Review For Once-Daily HIV Treatment Bictegravir Plus LenacapavirMay 02
Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of 77.2% stake in Arcellx, Inc. (NasdaqGS:ACLX) from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others.Apr 29
Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Tubulis GmbH from a group of shareholders for $5 billion.Apr 08
Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Ouro Medicines, Inc. from Keymed Biosciences Inc. (SEHK:2162) and others for $2.2 billion.Mar 24+ 1 more update
Gilead Sciences, Inc. Announces the Presentation of New Phase 3 ARTISTRY-1 and ARTISTRY-2 Trial Data At CROI 2026Feb 26
Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an agreement to acquire the remaining 88.50% stake in Arcellx, Inc. (NasdaqGS:ACLX) from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others for approximately $6.6 billion.Feb 23
Gilead Sciences, Inc. to Present New Hiv Treatment and Prevention Data At Croi 2026, with A Focus on Expanding OptionsFeb 17
Fda Approves Label Update for Kite's Yescarta®? for Relapsed/Refractory Primary Central Nervous System LymphomaFeb 06
Gilead Sciences, Inc. Announces New England Journal of Medicine Publishes Phase 3 ASCENT-04/KeyNOTE-D19 Results Supporting Trodelvy®? Plus Keytruda®? as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-Negative Breast CancerJan 22
Gilead Sciences, Inc. Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Effective December 18, 2025Dec 18
Deborah H. Telman to No Longer Serve as Executive Vice President, Corporate Affairs and General Counsel of Gilead Sciences, Inc. as of December 5, 2025Nov 20
Gilead Sciences, Inc. Joins Partners for Delivery of First Shipments of Breakthrough Twice-Yearly Lenacapavir for HIV Prevention to Sub-Saharan AfricaNov 18
Gilead Sciences, Inc.'s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ART-1 TrialNov 13
Gilead Sciences, Inc. to Showcase Interim Long-Term Efficacy Data for Livdelzi (Seladelpar) in Primary Biliary Cholangitis (Pbc) and Investigational Bulevirtide in Chronic Hepatitis DeltaOct 23
Gilead Sciences, Inc. Receives Health Canada Approval for the Treatment of Primary Biliary CholangitisOct 22
Gilead Sciences, Inc. to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025Oct 20+ 1 more update
Gilead Presents New Hiv Research Data At EACS 2025 – Driving Scientific Innovation in Treatment and PreventionOct 16
Gilead Sciences, Inc. Announces European Commission Authorizes Twice-Y Early Yeytuo (Lenacapavir) for HIV PreventionAug 26
Gilead Sciences, Inc. (NasdaqGS:GILD) announces an Equity Buyback for $6,000 million worth of its shares.Aug 08+ 2 more updates
Gilead Receives Positive CHMP Opinions Under Accelerated Review from European Medicines Agency for Twice-Yearly HIV PrEP Option in the European UnionJul 25+ 1 more update
Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approves Yeztugo (Lanacapavir) as Pre-Exposure ProphylaxisJun 19
Gilead Sciences, Inc. Announces Trodelvy Plus Keytruda®? Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast CancerJun 01
Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-03 Study of TrodelvyMay 23
Gilead's Livdelzi (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented At EASL 2025May 07+ 1 more update
Gilead Sciences, Inc. to Present Latest Advancements Across Primary Biliary Cholangitis and Viral HepatitisApr 29
Gilead Sciences, Inc. Declares Quarterly Dividend for the Second Quarter of 2025, Payable on June 27, 2025Apr 25+ 1 more update
Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-04/KeyNOTE-D19 StudyApr 21
Gilead Sciences, Inc. Presents New HIV Treatment and Cure Research Data At CROI 2025, Including an Investigational Long-Acting, Twice-Y Early Therapy OptionMar 12+ 1 more update
European Medicines Agency Validates Gilead's Marketing Authorization Application and Eu-Medicines for All Application for Twice-Yearly Lenacapavir for Hiv PreventionFeb 25
Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary CholangitisFeb 21
Gilead Sciences, Inc. Announces U.S. FDA Acceptance of Its New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority ReviewFeb 18
Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary CholangitisDec 13+ 1 more update
Kite, Gilead Company, Announces Results from Four Analyses That Continue to Demonstrate Durability of Response of Tecartus in Patients with R/R MCL and R/R B-ALL During 66th ASH Annual Meeting and ExpositionDec 10+ 1 more update
Gilead Sciences, Inc.' Company Kite Presents New Data Underscoring Curative Potential of Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASHDec 09
Gilead Sciences, Inc. Announces New England Journal of Medicine Publication of PURPOSE 2 ResultsNov 28
Gilead's Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary CholangitisNov 16
Gilead Sciences, Inc. Presents Full Purpose 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV GlasgowNov 13
Gilead Sciences, Inc. Declares Quarterly Dividend for the Fourth Quarter of 2024, Payable on December 30, 2024Nov 07
Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48Oct 21
Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024Oct 10+ 1 more update
Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention ConferenceOct 07
Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDAAug 15
Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in AsiaJun 27